GlassScriptPhysician profile
Paresh V Sheth
NPI 1669479911
$9,582.24
in general payments reported to CMS, 2019-2025
19 companies · $528 in 2025
The $528 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $52.19 · 2020: $5,565 · 2021: $1,541 · 2022: $98.67 · 2023: $664 · 2024: $1,134 · 2025: $528.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,398 · Travel and Lodging: $846 · Education: $81.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,398.03 |
| Travel and Lodging | $846.31 |
| Education | $81.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $6,271.76 | 2020-2021 | |
| Livanova USA, INC. | $1,366.49 | 2019-2024 | Vns Therapy, Vns Therapy Sentiva Model 1000 Generator |
| Abbvie INC. | $1,061.51 | 2021-2025 | Ubrelvy, Qulipta |
| Eisai INC. | $208.52 | 2024-2025 | |
| Teva Pharmaceuticals USA, INC. | $102.76 | 2025 | Austedo Xr |
| Astrazeneca Pharmaceuticals LP | $95.64 | 2022-2025 | |
| Pfizer INC. | $76.59 | 2025 | |
| Neurocrine Biosciences, INC. | $75.15 | 2023-2024 | Ingrezza, Ongentys |
| Lilly USA, LLC | $73.37 | 2019-2025 | Kisunla, Amyvid |
| Sk Life Science, INC. | $71.73 | 2022 | |
| Sunovion Pharmaceuticals INC. | $28.36 | 2021 | |
| Argenx US, INC. | $27.90 | 2024 | Vyvgart |
| Alnylam Pharmaceuticals INC. | $21.70 | 2024 | Onpattro |
| Acadia Pharmaceuticals INC | $20.11 | 2024 | Nuplazid |
| Axsome Therapeutics, INC. | $18.77 | 2025 | Symbravo |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Averitas Pharma INC. | $18.15 | 2024 | Qutenza |
| Avadel Cns Pharmaceuticals, LLC | $16.49 | 2024 | Lumryz |
| Lundbeck LLC | $13.81 | 2024 | Rexulti |
| Acorda Therapeutics, INC | $13.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paresh Sheth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.